Structure Therapeutics (GPCR) USPTO patents

Utility

Compounds and Compositions for Treating Conditions Associated with Lpa Receptor Activity

18 Jan 24

Haizhen Zhang, Michael Hanson, Andrew Jennings, Hui Lei, Xichen Lin, Qiong Zhang, Alexandre Cote, Anatoly M. Ruvinsky

Filed: 21 Oct 21

Utility

Heterocyclic GLP-1 Agonists

7 Dec 23

Qinghua MENG, Weiqiang XING, Xichen LIN, Andrew JENNINGS

Filed: 13 Oct 21

Utility

b6808ha5i52z30 9bh37t4k5p

19 Oct 23

Qinghua MENG, Weiqiang XING, Haizhen ZHANG, Xichen LIN, Hui LEI, Andrew JENNINGS

Filed: 8 Sep 21

Utility

1ive0gq08x p9xna54t7ocazmlzuzcnrk

12 Oct 23

The present disclosure provides LPA antagonists, as well as pharmaceutical compositions comprising the compounds disclosed herein.

Wei Huang, Hui Lei, Zhongmiao Xu, Haizhen Zhang, Qiong Zhang

Filed: 23 May 23

Utility

cwfmewqz88xzd8gcdxvxn7xrddbic7weq8v6lh7c9s vr2fsw9

12 Oct 23

Qinghua MENG, Weiqiang XING, Haizhen ZHANG, Xichen LIN, Hui LEI, Andrew JENNINGS

Filed: 6 Sep 21

Utility

c8tcliytiadkshxb3ruwy4kvc

21 Sep 23

This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Qinghua MENG, Andrew JENNINGS, Hui LEI, Xichen LIN

Filed: 28 Apr 21

Utility

3263w67fyajv0rzmzma8lirm0g34owpu

15 Aug 23

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol “APLNR”).

Haifeng Tang, Sarah Boyce, Michael Hanson, Zhe Nie

Filed: 28 Feb 19

Utility

m04bxnri4 ewlu2ttc12x6ahccttwr0lfmg9srifek57a51r5qe5qdv0vtvq

6 Apr 23

Qinghua MENG, Weiqiang XING, Haizhen ZHANG, Xichen LIN, Hui LEI, Andrew JENNINGS

Filed: 21 Sep 22